

Bauvois A , Larivière M , Watier H, Maillot F.

[Monoclonal Antibodies for Monogenic Diseases: A 2019 Update]

Med Sci (Paris). 2019, 35 : 1026-1028

Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM
Etiology and Outcomes of Thrombotic Microangiopathies.

Clin J Am Soc Nephrol. 2019, 14 : 557-566

Ben Djemaa S, Hervé-Aubert K, Lajoie L, Falanga A, Galdiero S, Nedellec S, Soucé M, Munnier E, Chourpa I, David S, Allard-Vannier E.

gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line.

Biomacromolecules. 2019, 20 : 3076-3086

Bequignon E, Dhommée C, Angely C, Thomas L, Bottier M, Escudier E, Isabey D, Coste A, Louis B, Papon JF, Gouilleux-Gruart V

FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?

Int J Mol Sci. 2019 Mar 19;20(6). pii: E1379

Colombat P, Lejeune J, Altmeyer A, Fouquereau E.

[A better management for a better care]

Bull Cancer. 2019, 106 : 55-63

Deveuve Q, Gouilleux-Gruart V, Thibault G, Lajoie L.

[The hinge region of therapeutic antibodies: major importance of a short sequence].

Med Sci (Paris). 2019, 35 : 1098-1105

Dumet C, Pottier J, Gouilleux-Gruart V, Watier H.

Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development.

MAbs. 2019, 11 : 1341-1350

Dumet C, Watier H.

[Which Immunoglobulin Heavy Chains for Which Immunostimulatory Antibodies?]

Med Sci (Paris). 2019, 35 : 975-981

Foucault-Fruchard L, Watier H, Antier D.

[Names and Indications of Antibodies Facing Regulations and Pharmaceutical Company Practices]

Med Sci (Paris). 2019, 35 : 1189-1193

Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet JP, de Maistre E, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T; French Working Group on Perioperative Haemostasis (GIHP).

Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR).

Arch Cardiovasc Dis. 2019, 112 : 199-216

Gruel Y, Rollin J.

Fibronectin: a double hit modulator in HIT?

Blood. 2019,133 : 891-892

Gruel Y, Kizlik-Masson C, Lenting P.
[Therapeutic antibodies in hemostasis. From the past to the future].
Med Sci (Paris). 2019, 35 : 1022-1025

Kizlik-Masson C, Deveuve Q, Zhou Y, Vayne C, Thibault G, McKenzie SE, Pouplard C, Loyau S, Gruel Y, Rollin J.
Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.
Blood. 2019, 133 : 2427-2435

Larivière M, Pèlegriin A, Martineau P, Watier H.
[Players From the Program Investments for the Future: MAbImprove MabEx]
Med Sci (Paris) 2019. 35 : 1204-1205

Lasne D, Pouplard C, Nougier C, Eschwege V, Le Cam Duchez V, Proulle V, Smahi M, Harzallah I, Voisin S, Toulon P, Sobas F, Galinat H, Flaujac C, Ternisien C, Jeanpierre E; groupe d'études de la biologie des maladies hémorragiques du Groupe français d'études de l'hémostase et la thrombose.
Factor VIII assays in treated hemophilia A patients.
Ann Biol Clin (Paris). 2019, 77 : 53-65

Lejeune J, Brachet G, Watier H.
Evolutionary Story of the Low/Medium-Affinity IgG Fc Receptor Gene Cluster.
Front Immunol. 2019, 10 : 1297.

Martin C, Brachet G, Colas C, Allard-Vannier E, Kizlik-Masson C, Esnault C, Respaud R, Denevault-Sabourin C, Chourpa I, Gouilleux-Gruart V, Viaud-Massuard MC, Joubert N.
In Vitro Characterization and Stability Profiles of Antibody-Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation.
Pharmaceuticals (Basel). 2019 Dec 2;12(4)

Martineau P, Watier H, Pèlegriin A, Turtoi A.
Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France.
MAbs. 2019, 11 : 812-825

Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K.
Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms.
Neurosurgery. 2019, 84 : 77-83

Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnères M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlegriin A, Poul MA.
A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.
MAbs. 2019, 11 : 593-605

Pèlegriin A, Beck A, Watier H.
[A Word From the Coordinators]
Med Sci (Paris). 2019, 35 : 923

Pouplard C, Jeanpierre E, Lasne D, Le Cam Duchez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Ternisien C, Toulon P, Voisin S, Nougier C; groupe d'études de la biologie des maladies hémorragiques du Groupe français d'études de l'hémostase et la thrombose.
Factor IX assays in treated hemophilia B patients.
Ann Biol Clin (Paris). 2019, 77 : 41-52

Pouplard C, Galinat H, Ternisien C, Blanc Jouvan F, De Maistre E, Duchemin J, Flaujac C, Hézard N, Grand F, Le Cam-Duchez V, Marlu R, Mourey G, Nedelec F, Pineau-Vincent F, Repesse Y, Stépanian A, Szymezak J, Voisin S, Voyer AL, Jeanpierre E, Lasne D; French Study Group on Laboratory Management of bleeding disorders (BIMHO group). *Multicentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion®)*. *Haemophilia*. 2019, 25 : e327-e330

Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Rouillet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C. *Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)*. *Haemophilia*. 2019, 25 : 731-737

Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories. *Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study*. *Haemophilia*. 2019, 25 : 708-717

Tromeur C, Le Mao R, Jego P, El-Kouri D, Gruel Y, Pan-Petes B, Bertoletti L, Morange PE, Lemoigne E, Paleiron N, Leroyer C, Couturaud F. *[Risk factors for thromboembolic disease in young women-the role of hormones]*. [Article in French] *Rev Mal Respir*. 2019, 36 : 219-226

Vayne C, May MA, Bourguignon T, Lemoine E, Guery EA, Rollin J, Gruel Y, Pouplard C. *Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation*. *Thromb Haemost*. 2019, 119 : 1138-1146

(Pouplard C et Gruel Y) Yu JK, Iorio A, Edginton AN; WAPPS co-investigators. *Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review*. *Res Pract Thromb Haemost*. 2019, 3 : 528-541

2018

Alric C, Hervé-Aubert K, Aubrey N, Melouk S, Lajoie L, Mème W, Mème S, Courbebaisse Y, Ignatova AA, Feofanov AV, Chourpa I, Allard-Vannier E. *Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobe*. *Journal of Nanobiotechnology*. 2018, 16 : 18

Bourquard T, Musnier A, Puard V, Tahir S, Ayoub MA, Jullian Y, Boulo T, Gallay N, Watier H, Bruneau G, Reiter E, Crépieux P, Poupon A. *MABTope: A Method for Improved Epitope Mapping*. *J Immunol*. 2018, 201 : 3096-3105

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; FranceCoag Collaborators. *Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A*. *Haematologica*. 2018, 103 : 179-189

Castaneda DC, Dhommée C, Baranek T, Dalloneau E, Lajoie L, Valayer A, Arnoult C, Demattéi MV, Fouquenot D, Parent C, Heuzé-Vourc'h N, Gouilleux-Gruart V.

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment.
Front Immunol. 2018 Sep 28;9:2259

Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Blood Adv. 2018, 2 : 3360-3392

Deluce-Kakwata-Nkor N, Lamendour L, Chabot V, Héraud A, Ivanovic Z, Halary F, Dehaut F, Velge-Roussel F.

Differentiation of human dendritic cell subsets for immune tolerance induction.

Transfus Clin Biol. 2018, 25 : 90-95

Dumet C, Pottier J, Gouilleux V, Watier H.

New structural formats of therapeutic antibodies in rheumatology.

Joint Bone Spine 2018, 85 : 47-52

Gatault P, Al-Hajj S, Noble J, Chevallier E, Piollet M, Forconi C, Gaudy-Graffin C, Thibault G, Miquelstorena-Standley E, Halimi JM, Büchler M, Lemoine R, Baron C.

CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells.

Am J Transplant. 2018, 18 : 1904-1913

Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; French Working Group on perioperative hemostasis (GIHP).

Management Of Antiplatelet Therapy In Patients Undergoing Elective Invasive Procedures Proposals From The French Working Group On Perioperative Hemostasis (Gihp) And The French Study Group On Thrombosis And Hemostasis (Gfht) In Collaboration With The French Society For Anesthesia And Intensive Care (Sfar).

Arch Cardiovasc Dis. 2018,111 : 210-223

Gruel Y

Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts.

Lancet Haematol. 2018 May;5(5):e188-e189.

Humeau C, Darrouzain F, Gouilleux-Gruart V.

T lymphocyte immunophenotyping in bronchoalveolar lavage on AQUIOS CL® cytometer.

J Immunol Methods. 2018, 461 : 91-99

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Haemophilia. 2018, 24 : 211-220

Martin C, Kizlik-Masson C, Pèlegriin A, Watier H, Viaud-Massuard MC, Joubert N.

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

MAbs. 2018 Feb/Mar;10(2):210-221

Maruani A, Boccara O, Bessis D, Guibaud L, Vabres P, Mazereeuw-Hautier J, Barbarot S, Chiaverini C, Blaise S, Droitcourt C, Mallet S, Martin L, Lorette G, Woillard JB, Jonville-Bera AP, Rollin J, Gruel Y, Herbreteau D, Goga D, le Touze A, Leducq S, Gissot V, Morel B, Tavernier E, Giraudeau B; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique.

Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Trials. 2018, 19 : 340

Négrier C, Ducloy-Bouthors AS, Piriou V, De Maistre E, Stieltjes N, Borel-Derlon A, Colson P, Picard J, Lambert T, Claeysens S, Boileau S, Bertrand A, André MH, Fourrier F, Ozier Y, Sié P, Gruel Y, Tellier Z.

Postauthorization safety study of Clottafact[®], a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.
Vox Sang. 2018, 113 : 120-127

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeysens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petes B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaert M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSEMO): study protocol for a multicentric French national observational cross-sectional study.
BMJ Open. 2018 Jul 25;8(7):e022409.

Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E, Susen S, Sie P, Derex L.

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants Expert opinion of the Société Française de Neurologie Vasculaire (SFNV) [French Vascular Neurology Society] and the Groupe Français d'études sur l'Hémostase et la Thrombose (GFHT) [French study Group on Haemostasis and Thrombosis].
Eur J Neurol. 2018, 25 : 747-e52

Vandier C, Velge-Roussel F.

Regulation of human dendritic cell immune functions by ion channels.
Curr Opin Immunol. 2018, 52 : 27-31

Velge-Roussel F, Pelegrín P.

Editorial overview: Ion channels and immune cells: What ions could do for immune cells.
Curr Opin Immunol. 2018 Jun;52:vi-viii.

Watier H

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle.
Oncotarget. 2018, 9 : 32732-32733